Marianna Manfrini

1.4k total citations · 1 hit paper
21 papers, 868 citations indexed

About

Marianna Manfrini is a scholar working on Pathology and Forensic Medicine, Neurology and Rheumatology. According to data from OpenAlex, Marianna Manfrini has authored 21 papers receiving a total of 868 indexed citations (citations by other indexed papers that have themselves been cited), including 18 papers in Pathology and Forensic Medicine, 6 papers in Neurology and 5 papers in Rheumatology. Recurrent topics in Marianna Manfrini's work include Multiple Sclerosis Research Studies (18 papers), Peripheral Neuropathies and Disorders (6 papers) and Rheumatoid Arthritis Research and Therapies (5 papers). Marianna Manfrini is often cited by papers focused on Multiple Sclerosis Research Studies (18 papers), Peripheral Neuropathies and Disorders (6 papers) and Rheumatoid Arthritis Research and Therapies (5 papers). Marianna Manfrini collaborates with scholars based in Switzerland, United States and Canada. Marianna Manfrini's co-authors include Stephen L. Hauser, Ludwig Kappos, Harold Koendgen, Jerry S. Wolinsky, Douglas L. Arnold, Fabian Model, Shibeshih Belachew, Qing Wang, Corrado Bernasconi and Gavin Giovannoni and has published in prestigious journals such as Neurology, The Lancet Neurology and Journal of Neurology Neurosurgery & Psychiatry.

In The Last Decade

Marianna Manfrini

19 papers receiving 859 citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Contribution of Relapse-Independent Progression vs Relapse-Associated Worsening to Overall Confirmed Disability Accumulation in Typical Relapsing Multiple Sclerosis in a Pooled Analysis of 2 Randomized Clinical Trials

2020 344 citations Ludwig Kappos, Jerry S. Wolinsky et al. JAMA Neurology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Marianna Manfrini Switzerland	7	737	325	221	205	168	21	868
Tamara Miller United States	6	799 1.1×	319 1.0×	288 1.3×	244 1.2×	32 0.2×	23	958
M. Stojanovic Serbia	8	815 1.1×	361 1.1×	271 1.2×	241 1.2×	30 0.2×	18	1.0k
Giulia Fadda Canada	13	547 0.7×	449 1.4×	101 0.5×	69 0.3×	57 0.3×	33	784
N. А. Totolyan Russia	7	528 0.7×	446 1.4×	60 0.3×	196 1.0×	41 0.2×	50	720
T. Pickersgill United Kingdom	8	582 0.8×	253 0.8×	141 0.6×	193 0.9×	19 0.1×	12	730
Franz Felix Konen Germany	13	340 0.5×	181 0.6×	78 0.4×	91 0.4×	54 0.3×	42	509
Ernesto Roldán Spain	15	451 0.6×	224 0.7×	194 0.9×	416 2.0×	17 0.1×	26	884
Anna Maria Repice Italy	11	348 0.5×	207 0.6×	92 0.4×	67 0.3×	28 0.2×	23	495
Jason P. Mendoza United States	13	424 0.6×	111 0.3×	136 0.6×	219 1.1×	21 0.1×	36	604
Mercedes Espiño Spain	11	380 0.5×	202 0.6×	97 0.4×	140 0.7×	19 0.1×	17	481

Countries citing papers authored by Marianna Manfrini

Since Specialization

Citations

This map shows the geographic impact of Marianna Manfrini's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Marianna Manfrini with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Marianna Manfrini more than expected).

Fields of papers citing papers by Marianna Manfrini

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Marianna Manfrini. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Marianna Manfrini. The network helps show where Marianna Manfrini may publish in the future.

Co-authorship network of co-authors of Marianna Manfrini

This figure shows the co-authorship network connecting the top 25 collaborators of Marianna Manfrini. A scholar is included among the top collaborators of Marianna Manfrini based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Marianna Manfrini. Marianna Manfrini is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Vandenborne, Krista, Glenn A. Walter, Volker Straub, et al.. (2025). Quantitative Muscle Magnetic Resonance Outcomes in Patients With Duchenne Muscular Dystrophy. JAMA Neurology. 82(7). 734–734.

Hartung, Hans‐Peter, Thomas Berger, Robert Bermel, et al.. (2024). ENSEMBLE PLUS: final results of shorter ocrelizumab infusion from a randomized controlled trial. Journal of Neurology. 271(7). 4348–4360.

Hauser, Stephen L., Amit Bar‐Or, Martin S. Weber, et al.. (2023). Association of Higher Ocrelizumab Exposure With Reduced Disability Progression in Multiple Sclerosis. Neurology Neuroimmunology & Neuroinflammation. 10(2). 28 indexed citations

Schmierer, Klaus, Jerry S. Wolinsky, Bruno Brochet, et al.. (2022). 031 Long-term efficacy of ocrelizumab in primary progressive multiple sclerosis: 6.5-study years. Journal of Neurology Neurosurgery & Psychiatry. 93(6). A23.1–A23. 1 indexed citations

Wolbers, Marcel, Fabian Model, Shibeshih Belachew, et al.. (2022). Recurrent disability progression endpoints in multiple sclerosis clinical trials. Multiple Sclerosis Journal. 29(1). 130–139. 1 indexed citations

Weathers, Shiao‐Pei, John de Groot, Marianna Manfrini, et al.. (2021). Results of a phase I trial to assess the safety of macitentan in combination with temozolomide for the treatment of recurrent glioblastoma. Neuro-Oncology Advances. 3(1). vdab141–vdab141. 5 indexed citations

Giovannoni, Gavin, Ludwig Kappos, J. de Sèze, et al.. (2021). Risk of requiring a walking aid after 6.5 years of ocrelizumab treatment in patients with relapsing multiple sclerosis: Data from the OPERA I and OPERA II trials. European Journal of Neurology. 29(4). 1238–1242. 11 indexed citations

Bar‐Or, Amit, Christopher Harp, Anne Cross, et al.. (2020). Factors associated with baseline serum neurofilament light concentrations in relapsing and primary progressive multiple sclerosis patients in the ocrelizumab OPERA 1 and ORATORIO Trials (2420). Neurology. 94(15_supplement). 1 indexed citations

Kappos, Ludwig, Jerry S. Wolinsky, Gavin Giovannoni, et al.. (2020). Contribution of Relapse-Independent Progression vs Relapse-Associated Worsening to Overall Confirmed Disability Accumulation in Typical Relapsing Multiple Sclerosis in a Pooled Analysis of 2 Randomized Clinical Trials. JAMA Neurology. 77(9). 1132–1132. 344 indexed citations breakdown →

10.

Wolinsky, Jerry S., Douglas L. Arnold, Bruno Brochet, et al.. (2020). Long-term follow-up from the ORATORIO trial of ocrelizumab for primary progressive multiple sclerosis: a post-hoc analysis from the ongoing open-label extension of the randomised, placebo-controlled, phase 3 trial. The Lancet Neurology. 19(12). 998–1009. 103 indexed citations

11.

Hauser, Stephen L., Ludwig Kappos, Douglas L. Arnold, et al.. (2020). Five years of ocrelizumab in relapsing multiple sclerosis. Neurology. 95(13). e1854–e1867. 106 indexed citations

12.

Giovannoni, Gavin, Ludwig Kappos, J. de Sèze, et al.. (2020). Long-term Reduction of Confirmed Disability Progression and Time to Walking Aid After 6 Years of Ocrelizumab Treatment in Patients with Relapsing Multiple Sclerosis (1847). Neurology. 94(15_supplement). 3 indexed citations

13.

Benedict, Ralph H. B., J. de Sèze, Stephen L. Hauser, et al.. (2020). Clinically Meaningful Decline on SDMT Primarily Occurs Independently of Relapses and Is Slowed by Ocrelizumab in Patients with Multiple Sclerosis: Results from the Pooled OPERA Studies (1290). Neurology. 94(15_supplement). 1 indexed citations

14.

Jia, Xiaoming, Christopher Harp, Anne Cross, et al.. (2020). Blood Neurofilament Light Chain Levels and Association with Brain Volume Change in Patients with Primary Progressive Multiple Sclerosis and Relapsing Multiple Sclerosis Before and During Ocrelizumab Treatment (3926). Neurology. 94(15_supplement). 1 indexed citations

15.

Bar‐Or, Amit, Jonathan Calkwood, Cathy Chognot, et al.. (2020). Effect of ocrelizumab on vaccine responses in patients with multiple sclerosis. Neurology. 95(14). e1999–e2008. 230 indexed citations

16.

Kappos, Ludwig, Jerry S. Wolinsky, Gavin Giovannoni, et al.. (2019). Progression Independent of Relapse Activity (PIRA) in Patients with Relapsing Multiple Sclerosis. SSRN Electronic Journal. 1 indexed citations

17.

Giovannoni, Gavin, Laura Airas, Riley Bove, et al.. (2019). Ocrelizumab Treatment Effect on Upper Limb Function in PPMS Patients with Disability: Subgroup Results of the ORATORIO Study to Inform the ORATORIO-HAND Study Design (P3.2-091). Neurology. 92(15_supplement). 3 indexed citations

18.

Stokmaier, Daniela, et al.. (2018). Effect of Ocrelizumab on Vaccine Responses in Patients With Multiple Sclerosis (S36.002). Neurology. 90(15_supplement). 19 indexed citations

19.

Kappos, Ludwig, Jerry S. Wolinsky, Gavin Giovannoni, et al.. (2018). 061 Ocrelizumab reduces disability progression independent of relapse activity in patients with relapsing multiple sclerosis (RMS) (ENCORE). Journal of Neurology Neurosurgery & Psychiatry. 89(6). A25.2–A25. 6 indexed citations

20.

Hauser, Stephen L., Bruno Brochet, Xavier Montalbán, et al.. (2018). Annualized Relapse Rate and Confirmed Disability Progression in Patients Receiving Continuous Ocrelizumab or Switching From Interferon Beta-1a to Ocrelizumab Therapy in the Open-Label Extension Period of the Phase III Trials of Ocrelizumab in Patients With Relapsing Multiple Sclerosis (P1.366). Neurology. 90(15_supplement). 3 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact